Objective :
Assessment of pipeline activities around client’s area of interest to support strategic decisions
Problem Statement:
A medium pharmaceutical client based in the United States with capabilities in cancer immunotherapy domain involved DelveInsight to analyze current pipeline activity of T-Cell Receptor (TCR) products for cancer treatment. They wished to identify currently active T-Cell Receptor (TCR) products in research and development for cancer treatment.
Our Methodology:
- Detailed Assessment of pipeline activity of T-Cell Receptor (TCR) products
- Clinical Trial Assessment of Clinical Stage products of T-Cell Receptor (TCR) arena
- Company Assessment via Funding/Collaboration/Partnership Analysis
- Analyst Comments on R&D developments
Results:
- Detailed pipeline profiles of T-Cell Receptor (TCR) products
- Additional comments on Inactive (Discontinued and Dormant) products.
- Therapeutic assessment of active pipeline products
- Detailed profiles of Companies with key coverage of collaboration/partnering activities
Our Related Services
Pipeline Assessment
Have Actionable Intelligence to support the development of your candidate through its clinical development journey
Market Assessment
Achieve Breakthroughs with all-encompassing Market Outlook Research
Sample Visuals
Get Visuals
Get Visuals
Transform your business with our case study. Download now and achieve your goals!
Related Insights
In-Licensing Opportunity
A large client based in USA, involved in drug delivery devices, with effective marketing and commercialization presence across the globe, wanted to in-license potential dMTS based drug delivery asset...
View CaseOut-Licensing Opportunity
A small pharmaceutical client based at Sweden, Europe with capabilities around a neonatal mesenchymal cells involved DelveInsight to identify a licensing partner for their stem cells product, from acr...
View CaseGo-To-Market Strategy
A medium pharmaceutical client based in United States with biosimilar commercial capabilities involved DelveInsight to identify commercial processes and strategies to launch their biosimilar in Europe...
View Case